Protara Therapeutics Files New $300M Shelf Registration, Launches $100M At-The-Market Offering
TARA sits 88% above its 52-week low of $2.77.
Summary
Protara Therapeutics filed a new shelf registration for up to $300 million in securities, including a $100 million At-The-Market (ATM) common stock offering, to fund its clinical development programs.
Key Events · Financing and Capital Events · TARA
-
New Shelf Registration Filed
Protara Therapeutics filed a new universal shelf registration statement for up to $300 million in common stock, preferred stock, debt securities, and warrants. This replaces a prior S-3 and includes $110.9 million in unsold securities from the previous registration, totaling over $410 million in potential offering capacity.
-
$100M At-The-Market (ATM) Offering Launched
The company established a new ATM program to sell up to $100 million of common stock through TD Cowen. This represents approximately 34.9% of the company's current market capitalization.
-
Purpose of Funds
Proceeds are earmarked for the clinical development of TARA-002 (for NMIBC and LMs) and IV Choline Chloride, other potential clinical programs, working capital, and general corporate purposes.
-
Significant Potential Dilution
The ATM program alone could result in approximately 34.86% dilution based on current outstanding shares, with the full shelf capacity representing over 140% of the current market cap. This follows a recent shareholder approval for an increase in authorized common stock.
Analysis · TARA · Life Sciences
Protara Therapeutics has filed a new universal shelf registration statement, allowing it to offer up to $300 million in various securities, including common stock, preferred stock, debt, and warrants. This new registration replaces a prior S-3 and carries forward $110.9 million in unsold securities, bringing the total potential offering capacity to over $410 million. Concurrently, the company established a new At-The-Market (ATM) equity program to sell up to $100 million of common stock through TD Cowen. This substantial capital raise, representing a significant portion of the company's market capitalization, is intended to fund ongoing clinical development for its TARA-002 and IV Choline Chloride programs, as well as general corporate purposes. While necessary for a clinical-stage biotech to extend its cash runway, the large potential dilution could create an overhang on the stock.
At the time of this filing, TARA was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286.3M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.